Tuberculosis and HIV coinfection

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 7, 2015, Pages

  Bruchfeld, Judith ^a   Correia Neves, Margarida ^b,c   Kallenius, Gunilla ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ISONIAZID; TUBERCULOSTATIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CASE FINDING; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION RISK; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIMARY INFECTION; PROPHYLAXIS; REINFECTION; TUBERCULOSIS; VACCINATION; COINFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; RISK FACTOR; TREATMENT OUTCOME;

MYCOBACTERIUM TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; COINFECTION; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84929369624     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017871     Document Type: Article

References (142)

1. Reference is also in this subject collection.
2. Allavena C, Rodallec A, Secher S, Reliquet V, Baffoin S, An-dré-Garnier E, Billaud E, Raffi F, Ferré V. 2013. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. J Med Virol 85: 1878-1882.
3. Allwood MDM, Lee YC, Salaniponi FM, Nyangulu DS, Kup-pysamu I, et al. 1997. Case-finding with a single sputum smear and household bleach (abstract). Int J Tuberc Lung Dis 1: S144.
4. Andersen P, Kaufmann SHE. 2014. Novel vaccination strat-egies against tuberculosis. Cold Spring Harb Perspect Med 4: a018523.
5. Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW, Tugela Ferry Care Research Collaboration. 2008. Exogenous reinfec-tion as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 198: 1582-1589.
6. Ansari AW, Kamarulzaman A, Schmidt RE. 2013. Multifac-eted impact of host C-C chemokine CCL2 in the immunopathogenesis of HIV-1/co-infection. Front Immunol 4: 312.
7. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P, Leibowitch J. 1997. Positive effects of combined antiretroviral therapy on CD4þ T cell homeo-stasis and function in advanced HIV disease. Science 277: 112-116.
8. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. 2001. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tu-berc Lung Dis 5: 225-232.
9. Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, Pitchenik AE, Woodley C, Cauthen G, Jarvis WR. 1992. Hospital outbreak of multidrug-resistant My-cobacterium tuberculosis infections. Factors in transmis-sion to staff and HIV-infected patients. JAMA 268: 1280-1286.
10. Behar SM. 2013. Antigen-specific CD8(þ) T cells and pro-tective immunity to tuberculosis. Adv Exp Med Biol 783: 141-163.
11. Behar SM, Divangahi M, Remold HG. 2010. Evasion of innate immunity by Mycobacterium tuberculosis: Is death an exit strategy? Nat Rev Microbiol 8: 668-674.
12. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Vicaut E, Lagrange PH, Sereni D, Autran B. 2006. Explosion of tuberculin-specific Th1-responses in-duces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20: F1-F7.
13. Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S, Delcey V, Vicaut E, Sereni D, Autran B, et al. 2009. Tuberculosis-associated immune restoration syn-drome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gd T cells. J Immunol 183: 3915-3923.
14. Brenchley JM, Douek DC. 2008. HIV infection and the gas-trointestinal immune system. Mucosal Immunol 1: 23-30.
15. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, Longuet P, Leport C, Vildé JL. 2004. Determinants of immune reconstitution inflammatory syn-drome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 39: 1709-1712.
16. Burman W, Weis S, Vernon A, Khan A, Benator D, Jones B, Silva C, King B, LaHart C, Mangura B, et al. 2007. Fre-quency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11: 1282-1289.
17. Camacho RJ. 2012. Special aspects of the treatment of HIV-2-infected patients. Intervirology 55: 179-183.
18. Carow B, Ye X, Gavier-Widen D, Bhuju S, Oehlmann W, Singh M, Sköld M, Ignatowicz L, Yoshimura A, Wigzell H, et al. 2011. Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tu-berculosis control in an interferon-g (IFN-g)-dependent manner. J Biol Chem 286: 26873-26887.
19. Charalambous S, Grant AD, Moloi V, Warren R, Day JH, van Helden P, Hayes RJ, Fielding KL, De Cock KM, Chaisson RE, et al. 2008. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 12: 942-948.
20. Chevalier MF, Weiss L. 2013. The split personality of regu-latory T cells in HIV infection. Blood 121: 29-37.
21. Cohn DL, O’Brien RJ. 1998. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiolog-ical studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 2: 16-26.
22. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. 2002. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4: 165-176.
23. Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK, Lawrie D, Stevens W, Montaner LJ, Sanne I, et al. 2011. Natural killer cell activation distinguishes Myco-bacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIVand HIV/MTB coinfection. J Acquir Immune Defic Syndr 58: 309-318.
24. Corbeau P, Reynes J. 2011. Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood 117: 5582-5590.
25. Corbett EL, MacPherson P. 2013. Tuberculosis screening in high human immunodeficiency virus prevalence settings: Turning promise into reality. Int J Tuberc Lung Dis 17: 1125-1138.
26. Coronado VG, Beck-Sague CM, Hutton MD, Davis BJ, Nicholas P, Villareal C, Woodley CL, Kilbum JO, Crawford JT, Frieden TR, et al. 1993. Transmission of multi-drug-resistant Mycobacterium tuberculosis among per-sons with human immunodeficiency virus infection in an urban hospital: Epidemiologic and restriction frag-ment length polymorphism analysis. J Infect Dis 168: 1052-1055.
27. Costiniuk CT, Jenabian MA. 2014. The lungs as anatomical reservoirs of HIV infection. Rev Med Virol 24: 35-54.
28. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, Fine PE, Glynn JR. 2010. Re-current TB: Relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 24: 417-426.
29. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, Hopewell PC. 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymor-phisms. N Engl J Med 326: 231-235.
30. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. 2006. PD-1 expression on HIV-specific T cells is asso-ciated with T-cell exhaustion and disease progression. Nature 443: 350-354.
31. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, Hunt P, Martin JN, Kahn JO, Levy J, et al. 2004. Immune activation set point during early HIV infection predicts subsequent CD4þ T-cell changes independent of viral load. Blood 104: 942-947.
32. Del Corno M, Liu QH, Schols D, de Clercq E, Gessani S, Freedman BD, Collman RG. 2001. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated pro-tein kinases in primary macrophages mediated by calci-um-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98: 2909-2916.
33. Douek D. 2007. HIV disease progression: Immune activa-tion, microbes, and a leaky gut. Top HIV Med 15: 114-117.
34. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, et al. 1992. An outbreak of multidrug-resistant tu-berculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326: 1514-1521.
35. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ. 2006. Suppressor of cytokine signaling 1 reg-ulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7: 33-39.
36. Fitzgerald-Bocarsly P, Jacobs ES. 2010. Plasmacytoid den-dritic cells in HIV infection: Striking a delicate balance. J Leukoc Biol 87: 609-620.
37. French MA, Price P, Stone SF. 2004. Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-1627.
38. Garrait V, Cadranel J, Esvant H, Herry I, Morinet P, Mayaud C, Israël-Biet D. 1997. Tuberculosis generates a microen-vironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 159: 2824-2830.
39. Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, Saathoff E, Boehme C, Geis S, Maboko L, Singh M, et al. 2008. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 198: 1590-1598.
40. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Re-ither K, Heeregrave EJ, Casazza JP, Ambrozak DR, Louder M, Ampofo W, et al. 2010. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 207: 2869-2881.
41. Getahun H, Gunneberg C, Granich R, Nunn P. 2010. HIV infection-associated tuberculosis: The epidemiology and the response. Clin Infect Dis 50: S201-S207.
42. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. 2000. Impact of the HIV epidemic on the spread of other diseases: The case of tuberculosis. AIDS 14: S47-S56.
43. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. 1996. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157: 1271-1278.
44. Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. 1998. The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall anti-gen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and anti-inflammatory cytokines. J Infect Dis 177: 1332-1338.
45. Hartigan-O’Connor DJ, Hirao LA, McCune JM, Dandekar S. 2011. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIVAIDS 6: 221-227.
46. Haas A, Zimmermann K, Oxenius A. 2011. Antigen-dependent and-independent mechanisms of T and B cell hy-peractivation during chronic HIV-1 infection. J Virol 85: 12102-12113.
47. Havlir DV, Barnes PF. 1999. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340: 367-373.
48. Hiroi T, Goto H, Someya K, Yanagita M, Honda M, Yama-naka N, Kiyono H. 2001. HIV mucosal vaccine: Nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1-and Th2-deficient conditions. J Immunol 167: 5862-5867.
49. Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, Shioda T, Rom WN, Weiden M. 2002. Maximal HIV-1 replication in alveolar macrophages during tuberculosis re-quires both lymphocyte contact and cytokines. J Exp Med 195: 495-505.
50. Hoshino Y, Tse DB, Rochford G, Prabhakar S, Hoshino S, Chitkara N, Kuwabara K, Ching E, Raju B, Gold JA, et al. 2004. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 rep-lication in human macrophages. J Immunol 172: 6251-6258.
51. Hoshino Y, Hoshino S, Gold JA, Raju B, Prabhakar S, Pine R, Rom WN, Nakata K, Weiden M. 2007. Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis. J Infect Dis 195: 1303-1310.
52. Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. 2008. The role of the thymus in HIV infection: A 10 year perspective. AIDS 22: 171-184.
53. Houben RM, Crampin AC, Ndhlovu R, Sonnenberg P, God-frey-Faussett P, Haas WH, Engelmann G, Lombard CJ, Wilkinson D, Bruchfeld J, et al. 2011. Human immuno-deficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis 15: 24-31.
54. ISDA. 2013. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Update by the HIV Medicine Association of the Infec-tious Diseases Society of America. Clin Infect Dis 39: 609-629.
55. Israel-Biet D, Cadranel J, Beldjord K, Andrieu JM, Jeffrey A, Even P. 1991. Tumor necrosis factor production in HIV-seropositive subjects. Relationship with lung oppor-tunistic infections and HIV expression in alveolar mac-rophages. J Immunol 147: 490-494.
56. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, et al. 2008. Tim-3 expression defines a novel popu-lation of dysfunctional T cells with highly elevated fre-quencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779.
57. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson RJ. 2009. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 180: 1262-1270.
58. Kanwar B, Favre D, McCune JM. 2010. Th17 and regulatory T cells: Implications for AIDS pathogenesis. Curr Opin HIVAIDS 5: 151-157.
59. Kato-Maeda M, Small PM. 2000. How molecular epidemi-ology has changed what we know about tuberculosis. West J Med 172: 256-259.
60. Kaufmann SH, McMichael AJ. 2005. Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat Med 11: S33-S44.
61. Kawahara M, Hashimoto A, Toida I, Honda M. 2002 Oral recombinant Mycobacterium bovis bacillus CalmetteGuerin expressing HIV-1 antigens as a freeze-dried vac-cine induces long-term, HIV-specific mucosal and sys-temic immunity. Clin Immunol 105: 326-331.
62. Kedzierska K, Crowe SM, Turville S, Cunningham AL. 2003. The influence of cytokines, chemokines and their recep-tors on HIV-1 replication in monocytes and macro-phages. Rev Med Virol 13: 39-56.
63. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. 2010. Treatment of active tuberculosis in HIV-coinfected patients: A systematic review and meta-analysis. Clin Infect Dis 50: 1288-1299.
64. Kompala T, Shenoi SV, Friedland G. 2013. Transmission of tuberculosis in resource-limited settings. Curr HIV/AIDS Rep 10: 264-272.
65. Kwan CK, Ernst JD. 2011. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev 24: 351-376.
66. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. 2013. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 43: 1995-2002.
67. Landay AL, Schade SZ, Takefman DM, Kuhns MC, McNa-mara AL, Rosen RL, Kessler HA, Spear GT. 1993. Detection of HIV-1 provirus in bronchoalveolar lavage cells by polymerase chain reaction. J Acquir Immune Defic Syndr 6: 171-175.
68. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, Toossi Z. 2001. Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 184: 1127-1133.
69. Lawn SD, Bekker LG, Miller RF. 2005a. Immune reconstitu-tion disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5: 361-373.
70. Lawn SD, Badri M, Wood R. 2005b. Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort. AIDS 19: 2109-2116.
71. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. 2010. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tu-berculosis in settings with limited health-care resources. Lancet Infect Dis 10: 489-498.
72. Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. 2013. Management of HIV-associated tuberculosis in resource-limited settings: A state-of-the-art review. BMC Med 11: 253.
73. Lee SS, Meintjes G, Kamarulzaman A, Leung CC. 2013. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected per-sons. Respirology 18: 912-922.
74. Li J, Munsiff SS, Driver CR, Sackoff J. 2005. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin-or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 41: 83-91.
75. Lim A, D’Orsogna L, Price P, French MA. 2008. Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res Ther 5: 9.
76. Locher CP, Witt SA, Kassel R, Dowell NL, Fujimura S, Levy JA. 2005. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4þ cell prolif-eration and activation. J Gen Virol 86: 1171-1179.
77. Manches O, Frieta D, Bhardwaj N. 2013. Dendritic cells in progression and pathology of HIV infection. Trends Immunol 35: 114-122.
78. Mancino G, Placido R, Bach S, Mariani F, Montesano C, Ercoli L, Zembala M, Colizzi V. 1997. Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells. J Infect Dis 175: 1531-1535.
79. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. 2006. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 53: 357-363.
80. Marais S, Meintjes G, Pepper DJ, Dodd LE, Schutz C, Ismail Z, Wilkinson KA, Wilkinson RJ. 2013. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 56: 450-460.
81. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. 2011a. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 365: 11-20.
82. Martinson NA, Hoffmann CJ, Chaisson RE. 2011b. Epidemiology of tuberculosis and HIV: Recent advances in understanding and responses. Proc Am Thorac Soc 8: 288-293.
83. Matthews K, Ntsekhe M, Syed F, Scriba T, Russell J, Tiba-zarwa K, Deffur A, Hanekom W, Mayosi BM, Wilkinson RJ, et al. 2012. HIV-1 infection alters CD4þ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur J Immunol 42: 147-157.
84. Mazurek J, Ignatowicz L, Kallenius G, Jansson M, Pawlowski A. 2012. Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection. Eur J Immunol 42: 1192-1202.
85. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowtiz M. 2004. Primary HIV-1 infection is associated with preferential de-pletion of CD4þ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
86. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, et al. 2008a. Tuberculosis-associated immune recon-stitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523.
87. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, Seldon R, Pepper DJ, Rebe K, Mouton P, et al. 2008b. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 178: 1083-1089.
88. Moir S, Chun TW, Fauci AS. 2011. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 6: 223-248.
89. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern, Central Africa. 2010. Immune re-constitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic re-view and meta-analysis. Lancet Infect Dis 10: 251-261.
90. Nakata K, Weiden M, Harkin T, Ho D, Rom WN. 1995. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: Ev-idence for genetic differences in HIV-1 between lung and blood macrophage populations. Mol Med 1: 744-757.
91. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y, Weiden M. 1997. Mycobacterium tuberculosis en-hances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 155: 996-1003.
92. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, Ramachandran R, Locht C, Jawahar MS, Narayanan PR. 2010. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis 201: 691-703.
93. Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortún J, Pérez-Elías MJ, Gomez-Mampaso E, Moreno S. 2002. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch In-tern Med 162: 97-99.
94. Neaton JD, Neuhaus J, Emery S. 2010. Soluble biomarkers and morbidity and mortality among people infected with HIV: Summary of published reports from 1997 to 2010. Curr Opin HIVAIDS 5: 480-490.
95. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wen-del K, Cronin W, Hooper N, Bishai W, Sterling TR. 2004. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: A compar-ison by HIV serostatus and rifamycin use. Clin Infect Dis 38: 731-736.
96. Nixon DE, Landay AL. 2010. Biomarkers of immune dys-function in HIV. Curr Opin HIVAIDS 5: 498-503.
97. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. 2014. In search of a new para-digm for protective immunity to TB. Nat Rev Microbiol 12: 289-299.
98. Nunn PP, Elliott AM, McAdam KP. 1994. Tropical res-piratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countries. Thorax 49: 511-518.
99. Olalla J, Pulido F, Rubio R, Costa MA, Monsalvo R, Palenque E, Costa JR, Del PA. 2002. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis 6: 71-75.
100. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. 1993. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342: 268-272.
101. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H. 2007. HIV impairs TNF-a mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 179: 6973-6980.
102. Pathak S, Wentzel-Larsen T, Asjo B. 2010. Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages. Infect Immun 78: 4022-4032.
103. Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kalle-nius G. 2012. Tuberculosis and HIV co-infection. PLoS Pathog 8: e1002464.
104. Pearl JE, Khader SA, Solache A, Gilmartin L, Ghilardi N, deSauvage F, Cooper AM. 2004. IL-27 signaling compromises control of bacterial growth in mycobacteria-infect-ed mice. J Immunol 173: 7490-7496.
105. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Williams JC, Mandala JK, Kaboto M, et al. 1995. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 332: 779-784.
106. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Myco-bacterium tuberculosis complex discriminate between an-cient and modern lineages. PLoS Pathog 7: e1001307
107. Ranjbar S, Jasenosky LD, Chow N, Goldfeld AE. 2012. Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog 8: e1002620.
108. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. 2006. Inci-dence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 42: 418-427.
109. Reuter MA, Pecora ND, Harding CV, Canaday DH, McDonald D. 2010. Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells. J Virol 84: 8549-8560.
110. Rieder HL. 1999. Epidemiologic basis of tuberculosis control. International Union against Tuberculosis and Lung Disease, Paris.
111. Roca FJ, Ramakrishnan L. 2013. TNF dually mediates resis-tance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153: 521-534.
112. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, Salinas-Carmona MC. 2006. Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses 22: 45-51.
113. Rothe C, Schlaich C, Thompson S. 2013. Healthcare-asso-ciated infections in sub-Saharan Africa. J Hosp Infect 85: 257-267.
114. Ryo A, Tsurutani N, Ohba K, Kimura R, Komano J, Nishi M, Soeda H, Hattori S, Perrem K, Yamamoto M, et al. 2008. SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci 105: 294-299.
115. Sauce D, Elbim C, Appay V. 2013. Monitoring cellular immune markers in HIV infection: From activation to ex-haustion. Curr Opin HIVAIDS 8: 125-131.
116. Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S, Marriott D, Pett S, Nanan R, Cooper DA, et al. 2009. Proliferation of weakly suppressive regu-latory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobac-terial immune restoration disease. Eur J Immunol 39: 391-403.
117. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320: 545-550.
118. Shattock RJ, Friedland JS, Griffin GE. 1993. Modulation of HIV transcription in and release from human monocytic cells following phagocytosis of Mycobacterium tuberculo-sis. Res Virol 144: 7-12.
119. Sierra-Madero JG, Toossi Z, Hom DL, Finegan CK, Hoenig E, Rich EA. 1994. Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status. J Infect Dis 169: 18-27.
120. Simonney N, Dewulf G, Herrmann JL, Gutierrez MC, Vic-aut E, Boutron C, Leportier M, Lafaurie M, Abgrall S, Sereni D, et al. 2008. Anti-PGL-Tb1 responses as an in-dicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb) 88: 453-461.
121. Skolimowska KH, Rangaka MX, Meintjes G, Pepper DJ, Seldon R, Matthews K, Wilkinson RJ, Wilkinson KA. 2012. Altered ratio of IFN-g/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV-tu-berculosis immune reconstitution inflammatory syn-drome. PLoS ONE 7: e46481.
122. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK. 1994. The epidemiology of tuberculosis in San Francisco. A popu-lation-based study using conventional and molecular methods. N Engl J Med 330: 1703-1709.
123. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold min-ers. J Infect Dis 191: 150-158.
124. Sotgiu G, Centis R, D’ambrosio L, Battista Migliori G. 2014. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a017822.
125. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. 2002. CD4 T cell depletion is linked di-rectly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 169: 3400-3406.
126. Spear GT, Kessler HA, Rothberg L, Phair J, Landay AL. 1990. Decreased oxidative burst activity of monocytes from asymptomatic HIV-infected individuals. Clin Immunol Immunopathol 54: 184-191.
127. Styblo K. 1989. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis 11: S339-346.
128. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, San-thanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, et al. 2010. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuber-culosis: A randomized clinical trial. Am J Respir Crit Care Med 181: 743-751.
129. Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R, Chegou NN, Maartens G, Rangaka MX, Rebe K, et al. 2011. Hypercytokinaemia accom-panies HIV-tuberculosis immune reconstitution inflam-matory syndrome. Eur Respir J 37: 1248-1259.
130. Tansuphasawadikul S, Saito W, Kim J, Phonrat B, Dhitavat J, Chamnachanan S, Pitisuttithum P. 2007. Outcomes in HIV-infected patients on antiretroviral therapy with tu-berculosis. Southeast Asian J Trop Med Public Health 38: 1053-1060.
131. Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA. 1997. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macro-phages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 15: 325-331.
132. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugyenyi P, Mugerwa RD, et al. 2001. Increased replication of HIV-1 at sites of Mycobac-terium tuberculosis infection: Potential mechanisms of viral activation. J Acquir Immune Defic Syndr 28: 1-8.
133. UNAIDS. 2012. Report on the global AIDS epidemic. United Nations, New York.
134. Van den Bergh R, Vanham G, Raes G, De Baetselier P, Coleb-unders R. 2006. Mycobacterium-associated immune reconstitution disease: Macrophages running wild? Lancet Infect Dis 6: 2-3; author reply 4-5.
135. Vassallo M, Mercie P, Cottalorda J, Ticchioni M, Dellamon-ica P. 2012. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: A system-atic literature review. Virol J 9: 174.
136. Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, Arthur LO, Farrar WL, Wahl LM. 1989. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 142: 3553-3559.
137. Wang X, Cao Z, Jiang J, Li Y, Dong M, Ostrowski M, Cheng X. 2011. Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculo-sis. J Infect 62: 292-300.
138. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. 1995. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151: 129-135.
139. WHO. 2013. Global tuberculosis report. WHO, Geneva.
140. Worsley CM, Suchard MS, Stevens WS, Van Rie A, Murdoch DM. 2010. Multi-analyte profiling of ten cytokines in South African HIV-infected patients with immune re-constitution inflammatory syndrome (IRIS). AIDS Res Ther 7: 36.
141. Yu JS, Peacock JW, Jacobs WR Jr, Frothingham R, Letvin NL, Liao HX, Haynes BF. 2007. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immuno-deficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin Vaccine Immunol 14: 886-893.
142. Zhang Y, Nakata K, Weiden M, Rom WN. 1995. Mycobacterium tuberculosis enhances human immunodefi-ciency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 95: 2324-2331.